Yamagata Clinical Helicobacter pylori study group

Yamagata Clinical Helicobacter pylori study group - Yamagata Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002087

Enrollment

4000

Registered

2009-06-17

Start date

2000-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peptic ulcer

Interventions

H. pylori eradication therapy consisted of lansoprazole 30 mg or omeprazole 20 mg, plus amoxicillin 750 mg and clarithromycin 200 or 400 mg all twice daily for 7 days. Conventional antacid therapy co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with H. pylori-positive peptic ulcer were considered eligible.

Exclusion criteria

Exclusion criteria: Patients with a history of gastric cancer and those in whom endoscopy or biopsy at the time of registration revealed gastric cancer were excluded from the study.

Design outcomes

Primary

Measure	Time frame
Incident rate ratio (IRR) of gastric cancer between patients receiving and not receiving H. pylori eradication therapy until end of 2007.	—

Secondary

Measure	Time frame
The accumulated incidences of gastric cancer in patients with successful and unsuccessful H. pylori eradication	—

Countries

Japan

Contacts

Public ContactKatsuhiro Mabe

KKR Sapporo Medical Center Gastroenterology

kmabe@kkr-smc.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026